SCHEMBL6339684

SCHEMBL6339684

CN(C)Cc1[c]cccc1-c1cncnc1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 13/20 0.37
CYP3A4 P08684 12/20 0.37
CYP2C19 P33261 7/20 0.37
ALDH1A1 P00352 3/20 0.37
CLK4 Q9HAZ1 2/20 0.37
CYP2D6 P10635 13/20 0.35
HSD17B10 Q99714 4/20 0.35
CHRNB2 P17787 1/20 0.34
CHRNA4 P43681 1/20 0.34
CYP2A6 P11509 3/20 0.34
TDP1 Q9NUW8 4/20 0.33
ALOX15 P16050 2/20 0.33
KDM4E B2RXH2 2/20 0.33
HPGD P15428 1/20 0.33
ATM Q13315 1/20 0.32
HIF1A Q16665 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6331673 0.85 CYP2A6 (0.48) CYP1A2CYP3A4CYP2C19ALDH1A1CLK4
SCHEMBL16719738 0.83 CHRNB2 (0.35) CYP1A2CYP3A4CYP2C19CLK4CYP2D6
SCHEMBL6638777 0.80 TAAR1 (0.44) ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL6331970 0.74 CYP2D6 (0.40) CYP1A2CYP3A4CYP2C19ALDH1A1CLK4
SCHEMBL16720066 0.73 HSD17B1 (0.38) CYP3A4ALDH1A1CHRNB2CHRNA4
SCHEMBL16720106 0.73 HTR7 (0.39)
SCHEMBL6637613 0.72 CHRNB2 (0.39) CYP1A2CYP3A4CYP2C19ALDH1A1CYP2D6
SCHEMBL7393013 0.72 CYP2A6 (0.38) CYP1A2CYP3A4CYP2C19ALDH1A1CLK4
SCHEMBL6337574 0.71 KDM4E (0.38) CYP1A2CYP3A4CYP2C19ALDH1A1CYP2D6
SCHEMBL6324148 0.69 KDM4E (0.39) ALDH1A1CYP2D6KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6858616-B2 Nitrogen containing heterobicycles as factor Xa inhibitors BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-02-22 US disclosed
EP-1140871-A4 THROMBIN OR FACTOR XA INHIBITORS BRISTOL MYERS SQUIBB PHARMA CO (US) 2004-05-06 EP disclosed
EP-1337251-A1 MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS Bristol-Myers Squibb Pharma Company (US) 2003-08-27 EP disclosed
US-6500855-B1 NITROGEN CONTAINING AROMATIC HETEROCYCLES WITH ORTHO-SUBSTITUTED P1 GROUPS; ANTICOAGULANTS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-12-31 US disclosed
WO-2002102380-A1 MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2002-12-27 WO disclosed
US-6413980-B1 INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASE ENZYMES; ANTICOAGULANTS; THROMBOEMBOLIC DISORDERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-07-02 US disclosed
US-6369227-B1 BLOOD COAGULATION BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-04-09 US disclosed
EP-1140871-A1 THROMBIN OR FACTOR XA INHIBITORS Du Pont Pharmaceuticals Company (US) 2001-10-10 EP disclosed
EP-1140941-A1 NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS Du Pont Pharmaceuticals Company (US) 2001-10-10 EP disclosed
WO-2000039131-A1 NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 2000-07-06 WO disclosed
WO-2000039108-A1 THROMBIN OR FACTOR XA INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 2000-07-06 WO disclosed